Jie Dong1, Yaling Wu1, Hong Zhu1, Gan Li1, Mengen Lv1, Daxiao Wu1, Xiaotao Li1, Faming Zhu1, Hangjun Lv1. 1. Blood Centre of Zhejiang Province, Ministry of Health, Hangzhou, Zhejiang, People's Republic of China Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, Zhejiang, People's Republic of China.
Abstract
BACKGROUND: Nucleic acid amplification testing (NAT) is not yet obligatory in China for blood donor screening and the risk of enzyme immunoassay (EIA)-negative, NAT-reactive donations in Chinese blood donors has rarely been reported. The aim of this study was to screen a population of Chinese blood donors using a triplex individual-donation (ID)-NAT assay and assess the safety benefits of implementing NAT. MATERIALS AND METHODS: Between 1st August, 2010 and 31st December, 2011 all donations at a Chinese blood centre were screened individually using the Procleix® Ultrio® assay, a multiplex NAT assay for the detection of hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA and human immunodeficiency virus-1 (HIV-1) RNA. All donations were also screened for HBsAg, anti-HIV and anti-HCV using two different EIA for each marker. Samples with discordant results between NAT and EIA were further tested with an alternative NAT assay (Cobas® TaqMan®). Potential yield cases (serologically negative/NAT-reactive donors) were further evaluated when possible. RESULTS: During the study period a total of 178,447 donations were screened by NAT and EIA, among which 169 HBV NAT yield cases (0.095%) were detected. No N AT yield cases were found for HIV-1 or HCV. For the HBV NAT yield cases, follow-up results showed that 11 (6.51%) were probable or confirmed HBV window period infections, 5 (2.96%) were chronic HBV carriers and 153 (90.53%) were probable or confirmed occult HBV infections. There was a statistically significant difference between the NAT-positive rates for first-time vs repeat donations (0.472% vs 0.146%, respectively; P<0.001). DISCUSSION: Our data demonstrate that the potential HBV yield rate was 1:1,056 for blood donations in the Zhejiang province of China. Implementation of NAT will provide a significant increment in safety relative to serological screening alone.
BACKGROUND: Nucleic acid amplification testing (NAT) is not yet obligatory in China for blood donor screening and the risk of enzyme immunoassay (EIA)-negative, NAT-reactive donations in Chinese blood donors has rarely been reported. The aim of this study was to screen a population of Chinese blood donors using a triplex individual-donation (ID)-NAT assay and assess the safety benefits of implementing NAT. MATERIALS AND METHODS: Between 1st August, 2010 and 31st December, 2011 all donations at a Chinese blood centre were screened individually using the Procleix® Ultrio® assay, a multiplex NAT assay for the detection of hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA and human immunodeficiency virus-1 (HIV-1) RNA. All donations were also screened for HBsAg, anti-HIV and anti-HCV using two different EIA for each marker. Samples with discordant results between NAT and EIA were further tested with an alternative NAT assay (Cobas® TaqMan®). Potential yield cases (serologically negative/NAT-reactive donors) were further evaluated when possible. RESULTS: During the study period a total of 178,447 donations were screened by NAT and EIA, among which 169 HBV NAT yield cases (0.095%) were detected. No N AT yield cases were found for HIV-1 or HCV. For the HBV NAT yield cases, follow-up results showed that 11 (6.51%) were probable or confirmed HBV window period infections, 5 (2.96%) were chronic HBV carriers and 153 (90.53%) were probable or confirmed occult HBV infections. There was a statistically significant difference between the NAT-positive rates for first-time vs repeat donations (0.472% vs 0.146%, respectively; P<0.001). DISCUSSION: Our data demonstrate that the potential HBV yield rate was 1:1,056 for blood donations in the Zhejiang province of China. Implementation of NAT will provide a significant increment in safety relative to serological screening alone.
Authors: J Coste; H W Reesink; C P Engelfriet; S Laperche; S Brown; M P Busch; H T Cuijpers; R Elgin; B Ekermo; J S Epstein; O Flesland; H E Heier; G Henn; J M Hernandez; I K Hewlett; C Hyland; A J Keller; T Krusius; S Levicnik-Stezina; G Levy; C K Lin; A R Margaritis; L Muylle; C Niederhauser; C Neiderhauser; S Pastila; J Pillonel; J Pineau; C L van der Poel; C Politis; W K Roth; S Sauleda; C R Seed; D Sondag-Thull; S L Stramer; M Strong; E C Vamvakas; C Velati; M A Vesga; A Zanetti Journal: Vox Sang Date: 2005-05 Impact factor: 2.144
Authors: W K Roth; M P Busch; A Schuller; S Ismay; A Cheng; C R Seed; C Jungbauer; P M Minsk; D Sondag-Thull; S Wendel; J E Levi; M Fearon; G Delage; Y Xie; I Jukic; P Turek; H Ullum; V Tefanova; M Tilk; R Reimal; J Castren; M Naukkarinen; A Assal; C Jork; M K Hourfar; P Michel; R Offergeld; L Pichl; M Schmidt; V Schottstedt; E Seifried; F Wagner; M Weber-Schehl; C Politis; C K Lin; W C Tsoi; J O'Riordan; A Gottreich; E Shinar; V Yahalom; C Velati; M Satake; N Sanad; I Sisene; A H Bon; M Koppelmann; P Flanagan; O Flesland; E Brojer; M Lętowska; F Nascimento; E Zhiburt; S S Chua; D Teo; S Levicnik Stezinar; M Vermeulen; R Reddy; Q Park; E Castro; A Eiras; I Gonzales Fraile; P Torres; B Ekermo; C Niederhauser; H Chen; S Oota; L J Brant; R Eglin; L Jarvis; L Mohabir; J Brodsky; G Foster; C Jennings; E Notari; S Stramer; D Kessler; C Hillyer; H Kamel; L Katz; C Taylor; S Panzer; H W Reesink Journal: Vox Sang Date: 2011-09-21 Impact factor: 2.144
Authors: H Murokawa; A Yoshikawa; H Ohnuma; A Iwata; N Katoh; M Miyamoto; H Mine; H Emura; K Tadokoro Journal: Vox Sang Date: 2005-01 Impact factor: 2.144
Authors: Clive R Seed; Anthea Cheng; Susan L Ismay; Wayne V Bolton; Philip Kiely; Trevor J Cobain; Anthony J Keller Journal: Transfusion Date: 2002-10 Impact factor: 3.157
Authors: S H Kleinman; D M Strong; G G E Tegtmeier; P V Holland; J B Gorlin; C Cousins; R P Chiacchierini; L A Pietrelli Journal: Transfusion Date: 2005-08 Impact factor: 3.157
Authors: Angelo R Margaritis; Stewart M Brown; Clive R Seed; Philip Kiely; Bruno D'Agostino; Anthony J Keller Journal: Transfusion Date: 2007-10 Impact factor: 3.157